SKIN The Journal of Cutaneous Medicine

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen

Page s24

Poster PDF

Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb

Page s23

Poster PDF

Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies

A Blauvelt, B Strober, R Langley, D Burge, L Pisenti, M Yassine, S Kavanagh, C Arendt, R Rolleri, K Reich

Page S16

Poster PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Diamant Thaci, Alice Gottlieb, Kristian Reich, Jerry Bagel, Daniel Burge, Luke Peterson, Janice Drew, Catherine Arendt, Jolanta Weglowska

Page s4

Poster PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Vincent Piguet, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rolleri, Jolanta Weglowska

Page s3

Poster PDF

Search

Search Results

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)